Depression is a common condition characterised by low mood, anhedonia and a range of accompanying features.
Many people will experience depression, or another mental health disease, during their lifetime. A renewed public health effort has put depression and mental illness at the forefront of public life and has helped to reduce stigma that may have been associated with it.
Despite this focus of mental health, many of these conditions still go under-recognised and under-treated. Here we will give an overview of depression in adults, how its classified and some of the current therapies available.
While a NICE guideline does exist for depression in adults, it was first published in 2009. NICE are in the process of creating an updated guideline, but it remains in the draft stages and has been the subject of some controversy. An updated version of NICE clinical guidance 90 can be found here.
There are two major classifications systems used:
Depression is common, according to the World Health Organisation it affects 264 million people around the world.
It is a leading cause of disability and contributes significantly to the global burden of disease. The UK is no different.
In statistics published by the Mental Health Foundation in 2016, just under 20% of adults showed symptoms of anxiety or depression. A third of people who self-identified as having a mental health problem had never received a diagnosis from a professional.
Though the aetiology of depression is poorly understood, a number of risk factors have been identified.
The DSM-V provides a classification framework for depressive disorders.
The below criteria describe a framework that can be used to help classify and diagnose depression. It must be remembered that each patient must be approached as an individual and any assessment made in a holistic manner.
Depression (or Major Depressive Disorder) is defined by DSM-V as the presence of five of the following symptoms, for at least two weeks, one of which should be low mood or loss of interest/pleasure:
In addition the following must be present:
Depression may then be classified in one of three categories of severity
Describes patients with some features of depression not meeting the above definition.
Subthreshold depressive symptoms: Describes patients with a number of depressive symptoms (see above) not meeting the criteria described above.
Persistent subthreshold depressive symptoms: Describes subthreshold depressive symptoms that persists for two years or more.
Although depression is largely a clinical diagnosis, secondary causes or contributory factors may need to be screened for.
Tests to consider include:
The management of depression is multifaceted and should be tailored to the individual patient.
Adult patients should be asked about suicidal thoughts and ideation. This is a key part of any assessment. This NICE CKS page has a framework for assessing suicide risk.
Any patient deemed to be at risk should be discussed immediately with the local specialist mental health services for further assessment and a management plan.
NOTE: SSRIs and SNRIs have been implicated in an increased risk of suicide, suicidal ideation and self-harm, particularly below the age of 30. All patients commenced in this age group should have review within one week of starting therapy with weekly reviews for at least one month.
The initiation of antidepressants must be taken as a collaborative decision based upon guidelines and discussion with the patient.
The choice of antidepressant depends on a number of factors:
In general an SSRI like citalopram will be offered first line. Sertraline may be used in co-morbid patients as it has fewer drug-drug interactions. Consider the need for PPI cover, particularly in those taking NSAIDs.
A discussion must be had regarding the nature of antidepressants. The risk of suicide and overdose should be explained. Antidepressants often take time to be effective and initially anxiety may worsen. Once commenced, the advice in general is to continue for at least six months. They should not stop without discussion with a medical professional.
A number of psychosocial and psychological therapies are available to patients.
Follow-up is important to allow assessment of suicide risk, response to treatment and any other changes that may occur.
Continue to assess suicide risk and escalate as appropriate. Review and address any safeguarding concerns.
Those deemed to be at risk of suicide should be discussed with local mental health services. If they do not require admission, review should be frequent.
In general it takes two weeks for the effect of antidepressants to become apparent.
If after a month the response is minimal, consider dose adjustment or switching drug class.
Psychological and psychosocial therapies normally have a set course, patients should be monitored during this to evaluate for benefit.
As a general rule antidepressants should be continued for a minimum of six months. Of course adverse reactions or side effects may prevent this.
At six months a discussion should be had with appropriate patients about stopping antidepressants and the potential risks involved. Factors that help guide decision making includes current symptoms, previous mental health history and other exacerbating factors.
If medication is continued consider psychological therapies as an adjunct and the need to refer to specialist services.
Ongoing use should be again reviewed at two years (and prior if appropriate). Again a holistic view must be taken and the benefits and risk of continuing and discontinuing treatment evaluated.
Typically antidepressants will be withdrawn gradually over a four week period to reduce the incidence and severity of discontinuation symptoms.
NOTE: Stopping and switching antidepressants must be done with caution, and according to guidelines.
Have comments about these notes? Leave us feedback